This is also the case for ERBB2-specific NK-92/5.28.z cells, which are currently being tested in a local treatment setting in a phase I clinical trial in glioblastoma patients at the University Hospital Frankfurt am Main, Germany; the treatment has so far demonstrated safety and feasibility in the single-dose dose-escalation part of this trial [21]. Here, ERBB2 is linked to glioblastoma.